N-terminal truncation of salmon calcitonin leads to calcitonin antagonists. Structure activity relationship of N-terminally truncated salmon calcitonin fragments in vitro and in vivo.
Structural requirements for binding to the bone calcitonin (CT) receptor and for CT bioactivity both in vitro and in vivo were assessed for a series of N-terminally truncated, N alpha-acetylated, fragments of salmon calcitonin (sCT). Sequential deletion of amino acid residues from the amino-terminus of [Ala7]sCT-(2-32) peptide amide first led to partial agonists and, upon deletion of residues 1 to 7, to a high affinity antagonist, N alpha-acetyl-sCT-(8-32)-NH2. The presence of two separate domains within the sCT sequence is proposed: (I) a binding domain comprising residues 9-32 and (II) an activation domain requiring residues 3 to 6. N alpha-acetyl-sCT-(8-32)-NH2, in several bioassays including plasminogen activator release from LLC-PK1 cells (pA2 = 7.31), cAMP production in UMR-106-06 cells (pA2 = 7.81) and in the fetal rat long bone resorption assay showed potent antagonistic properties.
Feyen
J H
JH
Sandoz Pharma Ltd, Basel, Switzerland.
Cardinaux
F
F
Gamse
R
R
Bruns
C
C
Azria
M
M
Trechsel
U
U
D000107:Acetylation; D000818:Animals; D001862:Bone Resorption; D002116:Calcitonin / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D002460:Cell Line; D000242:Cyclic AMP / Q000096:biosynthesis; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D015394:Molecular Structure; D012516:Osteosarcoma / Q000378:metabolism; D010446:Peptide Fragments / Q000737:chemistry / Q000494:pharmacology*; D010960:Plasminogen Activators / Q000378:metabolism; D011869:Radioligand Assay; D051381:Rats; D014407:Tumor Cells, Cultured
D010446:Peptide Fragments; C028815:salmon calcitonin; D002116:Calcitonin; D000242:Cyclic AMP; D010960:Plasminogen Activators